Spotlight on Gastroenterology

Evan Dellon, MD, MPH
Credits: 2.0 CME
Hard to Swallow: Bridging Knowledge Gaps in Eosinophilic Esophagitis
Evan Dellon, MD, MPH
The Academy for Continued Healthcare Learning

Hard to Swallow: Bridging Knowledge Gaps in Eosinophilic Esophagitis

Start

Activity Details

Free CME
2.0 AMA PRA Category 1 Credit(s)
Released: June 4, 2021
Expires: June 4, 2022
120 minutes to complete

Accredited By

Target Audience

This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify patients with EoE using the latest diagnostic recommendations and criteria
  • Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
  • Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
  • Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
  • Indicate the potential roles of investigational treatments in EoE management plans

Activity Description

Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.

Faculty discussion will focus on:

  • Recognizing and diagnosing EoE
  • Treating EoE as a chronic disease
  • Novel developments in treatment

Statement of Educational Need

EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.

Agenda

Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic Treatment of EoE

Faculty

Evan Dellon, MD, MPH
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine, University of North Carolina at Chapel Hill
Chapel Hill, NC


Raquel Durban, MS, RD, CSP, LDN
Carolina Asthma & Allergy Center
Registered Dietitian
Charlotte, NC


Gary W. Falk, MD, MS
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA


Calies Menard-Katcher, MD, MSCS
Associate Professor of Pediatrics
Associate Director of Clinical Research for the GEDP
Division of Gastroenterology Hepatology and Nutrition
Department of Pediatrics
University of Colorado School of Medicine
Gastrointestinal Eosinophilic Diseases Program
Digestive Health Institute
Children's Hospital Colorado
Aurora, CO


Robert Pesek, MD
Medical Director, Asthma
Medical Director, Eosinophilic Gastrointestinal Disorders Clinic
Associate Professor of Pediatrics and Allergy/Immunology
Arkansas Children's Hospital and the University of Arkansas for Medical Sciences
Little Rock, AR


The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner, Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda

Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose

Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics, Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb, Interpace, Lucid, Regeneron, Shire/Takeda

Calies Menard-Katcher, MD, MSCS
Nothing to disclose

Robert Pesek, MD
Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Activity Details

Free CME
2.0 AMA PRA Category 1 Credit(s)
Released: June 4, 2021
Expires: June 4, 2022
120 minutes to complete

Accredited By

Target Audience

This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify patients with EoE using the latest diagnostic recommendations and criteria
  • Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
  • Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
  • Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
  • Indicate the potential roles of investigational treatments in EoE management plans

Activity Description

Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.

Faculty discussion will focus on:

  • Recognizing and diagnosing EoE
  • Treating EoE as a chronic disease
  • Novel developments in treatment

Statement of Educational Need

EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.

Agenda

Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic Treatment of EoE

Faculty

Evan Dellon, MD, MPH
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine, University of North Carolina at Chapel Hill
Chapel Hill, NC


Raquel Durban, MS, RD, CSP, LDN
Carolina Asthma & Allergy Center
Registered Dietitian
Charlotte, NC


Gary W. Falk, MD, MS
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA


Calies Menard-Katcher, MD, MSCS
Associate Professor of Pediatrics
Associate Director of Clinical Research for the GEDP
Division of Gastroenterology Hepatology and Nutrition
Department of Pediatrics
University of Colorado School of Medicine
Gastrointestinal Eosinophilic Diseases Program
Digestive Health Institute
Children's Hospital Colorado
Aurora, CO


Robert Pesek, MD
Medical Director, Asthma
Medical Director, Eosinophilic Gastrointestinal Disorders Clinic
Associate Professor of Pediatrics and Allergy/Immunology
Arkansas Children's Hospital and the University of Arkansas for Medical Sciences
Little Rock, AR


The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner, Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda

Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose

Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics, Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb, Interpace, Lucid, Regeneron, Shire/Takeda

Calies Menard-Katcher, MD, MSCS
Nothing to disclose

Robert Pesek, MD
Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Gastroenterology Presentations

0.25 CME
AGA Institute
Getting it Right in Ulcerative Colitis: A Clinical Guideline and Decision Tool-Based Approach

Getting it Right in Ulcerative Colitis: A Clinical Guideline and Decision Tool-Based Approach

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: April 22, 2022
Expires: April 21, 2023
15 minutes to complete

Provided By

This activity is provided by AGA. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

Gastroenterologists and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ standards of care for the management of inflammatory bowel disease (IBD) as presented in current guidelines
  • Apply IBD clinical decision support tools to risk stratify patients and aid in therapeutic selection
  • Select IBD therapies based on risk stratification and guideline recommendations

Activity Description

Ulcerative colitis as a disease can vary widely between patients in its course, complication risk, and treatment, making risk stratification an important component of care. However, traditional high-risk indicators are falling out of favor as more evidence-based, patient-specific tools are being developed. In this self-paced, interactive, infographic with video commentary, tool demonstrations, and case-based learning, participants will learn more about these tools and AGA guidelines and care pathway for assessing and treating patients with ulcerative colitis.

Faculty

Parambir S. Dulai, MD
Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology & Hepatology
Feinberg School of Medicine, Northwestern University
Evanston, IL


Dana Lukin, MD, PhD
Associate Professor, Clinical Medicine
Clinical Director, Translational Research
Jill Roberts Center for Inflammatory Bowel Disease
New York Presbyterian Hospital
Weill Cornell Medicine
New York, NY

Disclosure of Financial Relationships

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Parambir S. Dulai, MD, has affiliations with Gilead, Janssen, Lilly, Pfizer, Takeda (Consulting Fee); DigbiHealth (Ownership Interest [Stocks]); PreciDiag (Royalty).

Dana Lukin, MD, PhD, has affiliations with AbbVie, BMS, Boehringer Ingelheim, Janssen, Palatin Technologies, Pfizer (Consulting Fee).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Lobna Eldasher, PharmD, Medical Director, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic (Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to disclose.
Naemat Sandhu, MD, has no financial relationships to disclose.

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AGA Institute at education@gastro.org.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

Your Feedback is Important! 

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card. 

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by educational grants from Takeda Pharmaceuticals, U.S.A., Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: April 22, 2022
Expires: April 21, 2023
15 minutes to complete

Provided By

This activity is provided by AGA. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

Gastroenterologists and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ standards of care for the management of inflammatory bowel disease (IBD) as presented in current guidelines
  • Apply IBD clinical decision support tools to risk stratify patients and aid in therapeutic selection
  • Select IBD therapies based on risk stratification and guideline recommendations

Activity Description

Ulcerative colitis as a disease can vary widely between patients in its course, complication risk, and treatment, making risk stratification an important component of care. However, traditional high-risk indicators are falling out of favor as more evidence-based, patient-specific tools are being developed. In this self-paced, interactive, infographic with video commentary, tool demonstrations, and case-based learning, participants will learn more about these tools and AGA guidelines and care pathway for assessing and treating patients with ulcerative colitis.

Faculty

Parambir S. Dulai, MD
Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology & Hepatology
Feinberg School of Medicine, Northwestern University
Evanston, IL


Dana Lukin, MD, PhD
Associate Professor, Clinical Medicine
Clinical Director, Translational Research
Jill Roberts Center for Inflammatory Bowel Disease
New York Presbyterian Hospital
Weill Cornell Medicine
New York, NY

Disclosure of Financial Relationships

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Parambir S. Dulai, MD, has affiliations with Gilead, Janssen, Lilly, Pfizer, Takeda (Consulting Fee); DigbiHealth (Ownership Interest [Stocks]); PreciDiag (Royalty).

Dana Lukin, MD, PhD, has affiliations with AbbVie, BMS, Boehringer Ingelheim, Janssen, Palatin Technologies, Pfizer (Consulting Fee).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Lobna Eldasher, PharmD, Medical Director, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic (Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to disclose.
Naemat Sandhu, MD, has no financial relationships to disclose.

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AGA Institute at education@gastro.org.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

Your Feedback is Important! 

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card. 

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by educational grants from Takeda Pharmaceuticals, U.S.A., Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

0.25 CME
AGA Institute
Getting it Right in Crohn’s Disease: A Clinical Guideline and Decision Tool-Based Approach

Getting it Right in Crohn’s Disease: A Clinical Guideline and Decision Tool-Based Approach

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: April 22, 2022
Expires: April 21, 2023
15 minutes to complete

Provided By

This activity is provided by AGA. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

Gastroenterologists and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ standards of care for the management of inflammatory bowel disease (IBD) as presented in current guidelines
  • Apply IBD clinical decision support tools to risk stratify patients and aid in therapeutic selection
  • Select IBD therapies based on risk stratification and guideline recommendations

Activity Description

Despite evidence supporting usefulness of patient-specific risk stratification and personalized treatment, many patients with Crohn’s disease continue to be undertreated. In this activity, learners will explore new and available tools to help risk stratify patients with Crohn’s disease, predict the likelihood of response to various biologic therapies, and select appropriate treatment using these tools and AGA guidelines and care pathways. This activity provides tool demonstrations, video commentary, and case presentations all in one interactive, self-paced infographic.

Faculty

Parambir S. Dulai, MD
Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology & Hepatology
Feinberg School of Medicine, Northwestern University
Evanston, IL


Corey A. Siegel, MD, MS
Professor of Medicine and of The Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-Director, IBD Center
Dartmouth-Hitchcock Medical Center
Hanover, NH

Disclosure of Financial Relationships

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Parambir S. Dulai, MD, has affiliations with Gilead, Janssen, Lilly, Pfizer, Takeda (Consulting Fee); DigbiHealth (Ownership Interest [Stocks]); PreciDiag (Royalty).

Corey A. Siegel, MD, MS, has affiliations with AbbVie, BMS, Janssen, Lilly, Napo Pharmaceuticals, Pfizer, Prometheus Biosciences, Takeda, Trellus Health (Consulting Fee); AbbVie, Pfizer, Takeda (Grant/Research Support); Takeda (Speaker/Teacher); MiTest Health (Royalty).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Lobna Eldasher, PharmD, Medical Director, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic (Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to disclose.
Naemat Sandhu, MD, has no financial relationships to disclose.

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AGA Institute at education@gastro.org.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

Your Feedback is Important! 

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card. 

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by educational grants from Takeda Pharmaceuticals, U.S.A., Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: April 22, 2022
Expires: April 21, 2023
15 minutes to complete

Provided By

This activity is provided by AGA. Produced in collaboration with RMEI Medical Education, LLC.

Target Audience

Gastroenterologists and primary care clinicians involved in the care of patients with inflammatory bowel disease (IBD).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Employ standards of care for the management of inflammatory bowel disease (IBD) as presented in current guidelines
  • Apply IBD clinical decision support tools to risk stratify patients and aid in therapeutic selection
  • Select IBD therapies based on risk stratification and guideline recommendations

Activity Description

Despite evidence supporting usefulness of patient-specific risk stratification and personalized treatment, many patients with Crohn’s disease continue to be undertreated. In this activity, learners will explore new and available tools to help risk stratify patients with Crohn’s disease, predict the likelihood of response to various biologic therapies, and select appropriate treatment using these tools and AGA guidelines and care pathways. This activity provides tool demonstrations, video commentary, and case presentations all in one interactive, self-paced infographic.

Faculty

Parambir S. Dulai, MD
Associate Professor, Medicine
Director, GI Clinical Trials
Director, Precision Medicine
Division of Gastroenterology & Hepatology
Feinberg School of Medicine, Northwestern University
Evanston, IL


Corey A. Siegel, MD, MS
Professor of Medicine and of The Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-Director, IBD Center
Dartmouth-Hitchcock Medical Center
Hanover, NH

Disclosure of Financial Relationships

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Parambir S. Dulai, MD, has affiliations with Gilead, Janssen, Lilly, Pfizer, Takeda (Consulting Fee); DigbiHealth (Ownership Interest [Stocks]); PreciDiag (Royalty).

Corey A. Siegel, MD, MS, has affiliations with AbbVie, BMS, Janssen, Lilly, Napo Pharmaceuticals, Pfizer, Prometheus Biosciences, Takeda, Trellus Health (Consulting Fee); AbbVie, Pfizer, Takeda (Grant/Research Support); Takeda (Speaker/Teacher); MiTest Health (Royalty).

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Lobna Eldasher, PharmD, Medical Director, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic (Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to disclose.
Naemat Sandhu, MD, has no financial relationships to disclose.

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria for Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AGA Institute at education@gastro.org.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

Your Feedback is Important! 

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC. 
No supporter funding was used for the expense of this gift card. 

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by educational grants from Takeda Pharmaceuticals, U.S.A., Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Mirna Chehade, MD, MPH
1.25 AANP / CME
Global Education Group
Finding the Path in Eosinophilic Esophagitis: Interdisciplinary Strategies for Adult and Pediatric Patients

Finding the Path in Eosinophilic Esophagitis: Interdisciplinary Strategies for Adult and Pediatric Patients

Start

Activity Details

Free CME/AANP
1.25 AMA PRA Category 1 Credit(s)
1.25 AANP contact hour(s)
Released: December 10, 2021
Expires: December 10, 2022
75 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Target Audience

This program is intended for allergists/clinical immunologists, gastroenterologists, and other clinicians involved in the identification and management of patients with eosinophilic esophagitis (EoE).

Program Overview

During this Call-a-Colleague™ program, specialists in allergy/immunology and eosinophilic gastrointestinal disease will discuss the disease burden, pathophysiology, diagnosis, and current management of EoE. Faculty will also present clinical trial evidence for emerging treatment options as well as considerations for patients with other atopic conditions. A unique feature of the program will be the Call-a-Colleague™ sections in which our specialists will elicit additional insight from their multidisciplinary team members, such as a dietitian, a psychologist, and a pediatric gastroenterologist. The clinicians will provide their expertise regarding the mental health burden among patients, the use of an elimination diet to resolve symptoms, and clinical issues pertaining to pediatric patients with EoE.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the pathophysiologic mechanisms underlying EoE development, with a focus on potential therapeutic targets
  • Comprehensively assess pediatric and adult patients with suspected EoE to accelerate differential diagnoses and establish appropriate multidisciplinary care
  • Compare the clinical profiles, available trial evidence, and drawbacks of current and emerging treatment strategies for EoE
  • Longitudinally manage pediatric and adult patients with EoE based on symptoms, comorbidities, updated clinical guidelines, and therapeutic responses
  • Communicate with patients, caregivers, and members of the multidisciplinary team to ensure continuity of care and promote shared clinical decision-making

Faculty

Mirna Chehade, MD, MPH
Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York


Ikuo Hirano, MD
Professor of Medicine (Gastroenterology and Hepatology)
Northwestern University Feinberg School of Medicine
Chicago, Illinois


Jonathan Spergel, MD
Chief, Allergy Program
Children's Hospital of Philadelphia
Stuart E. Starr Chair of Pediatrics
Professor of Pediatrics
Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.25 contact hour(s) (which includes 0.0 hour(s) of pharmacology).

Instructions to Receive Credit

In order to receive credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Preactivity Questions.
  3. Review the activity content.
  4. Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation to receive credit.

Term of Offering

This activity was released on December 10, 2021, and is valid for one year. Requests for credit must be made no later than December 10, 2022.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Mirna Chehade, MD
Consulting Fee: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc., Bristol Myers Squibb, Ellodi Pharmaceuticals, Phathom Pharmaceuticals Regeneron Pharmaceuticals, Inc., Sanofi S.A, Shire plc, Takeda Pharmaceutical Company Limited.
Contracted Research: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc, Danone S.A., Ellodi Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Shire plc, Takeda Pharmaceutical Company Limited.

Ikuo Hirano, MD
Consultant: Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Avir, Celgene/Receptos/BMS, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calyx, Regeneron, Shire/Takeda.
Research funding: Adare/Ellodi, Allakos, AstraZeneca, Celgene/Receptos/BMS, Meritage, Regeneron, Shire/Takeda.

Jonathan Spergel, MD
Consultant: Abbott, Novartis, Regeneron, Sanofi.
Research funding: Celgene, Genentech, Novartis, Regeneron, Sanofi.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Kim Rodriguez - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose
Rose O’Connor, PhD, CHCP - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/AANP
1.25 AMA PRA Category 1 Credit(s)
1.25 AANP contact hour(s)
Released: December 10, 2021
Expires: December 10, 2022
75 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Target Audience

This program is intended for allergists/clinical immunologists, gastroenterologists, and other clinicians involved in the identification and management of patients with eosinophilic esophagitis (EoE).

Program Overview

During this Call-a-Colleague™ program, specialists in allergy/immunology and eosinophilic gastrointestinal disease will discuss the disease burden, pathophysiology, diagnosis, and current management of EoE. Faculty will also present clinical trial evidence for emerging treatment options as well as considerations for patients with other atopic conditions. A unique feature of the program will be the Call-a-Colleague™ sections in which our specialists will elicit additional insight from their multidisciplinary team members, such as a dietitian, a psychologist, and a pediatric gastroenterologist. The clinicians will provide their expertise regarding the mental health burden among patients, the use of an elimination diet to resolve symptoms, and clinical issues pertaining to pediatric patients with EoE.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe the pathophysiologic mechanisms underlying EoE development, with a focus on potential therapeutic targets
  • Comprehensively assess pediatric and adult patients with suspected EoE to accelerate differential diagnoses and establish appropriate multidisciplinary care
  • Compare the clinical profiles, available trial evidence, and drawbacks of current and emerging treatment strategies for EoE
  • Longitudinally manage pediatric and adult patients with EoE based on symptoms, comorbidities, updated clinical guidelines, and therapeutic responses
  • Communicate with patients, caregivers, and members of the multidisciplinary team to ensure continuity of care and promote shared clinical decision-making

Faculty

Mirna Chehade, MD, MPH
Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York


Ikuo Hirano, MD
Professor of Medicine (Gastroenterology and Hepatology)
Northwestern University Feinberg School of Medicine
Chicago, Illinois


Jonathan Spergel, MD
Chief, Allergy Program
Children's Hospital of Philadelphia
Stuart E. Starr Chair of Pediatrics
Professor of Pediatrics
Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.25 contact hour(s) (which includes 0.0 hour(s) of pharmacology).

Instructions to Receive Credit

In order to receive credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
  2. Complete the Preactivity Questions.
  3. Review the activity content.
  4. Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation to receive credit.

Term of Offering

This activity was released on December 10, 2021, and is valid for one year. Requests for credit must be made no later than December 10, 2022.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Mirna Chehade, MD
Consulting Fee: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc., Bristol Myers Squibb, Ellodi Pharmaceuticals, Phathom Pharmaceuticals Regeneron Pharmaceuticals, Inc., Sanofi S.A, Shire plc, Takeda Pharmaceutical Company Limited.
Contracted Research: Adare Pharma Solutions, Allakos Inc., AstraZeneca plc, Danone S.A., Ellodi Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Shire plc, Takeda Pharmaceutical Company Limited.

Ikuo Hirano, MD
Consultant: Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Avir, Celgene/Receptos/BMS, Eli Lilly, EsoCap, Gossamer Bio, Parexel/Calyx, Regeneron, Shire/Takeda.
Research funding: Adare/Ellodi, Allakos, AstraZeneca, Celgene/Receptos/BMS, Meritage, Regeneron, Shire/Takeda.

Jonathan Spergel, MD
Consultant: Abbott, Novartis, Regeneron, Sanofi.
Research funding: Celgene, Genentech, Novartis, Regeneron, Sanofi.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Kim Rodriguez - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose
Rose O’Connor, PhD, CHCP - Nothing to disclose
Jim Kappler, PhD - Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Maria T. Abreu, MD
1.5 CME
Global Education Group
Inflammatory Bowel Disease (IBD) eHealth Source™ Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up To Date? A Focus on Clinical Evidence and Guideline Recommendations

Inflammatory Bowel Disease (IBD) eHealth Source™ Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up To Date? A Focus on Clinical Evidence and Guideline Recommendations

Start

Activity Details

Free CME
1.5 AMA PRA Category 1 Credit(s)
Released: October 15, 2021
Expires: October 15, 2022
90 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of clinical gastroenterologists and specialist nurse practitioners and physician assistants involved in the treatment of patients with ulcerative colitis (UC).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Appropriately assess disease severity and activity to identify high-risk patients with UC who may be candidates for advanced treatment with biologics or small molecule inhibitor agents
  • Describe guideline recommendations and clinical trial evidence surrounding induction and maintenance therapies for moderate-to-severe UC
  • Implement treat-to-target strategies that utilize objective measures of remission as well as patient reported outcomes (PROs) to reach patient-centered treatment goals
  • Translate evidence to informed therapeutic selection when evaluating the positioning of biologics and small molecule inhibitors for first-line induction, maintenance, or next-line therapy

Activity Description

This multimedia IBD eHealth Source™ will provide published clinical evidence and guideline recommendations surrounding the stratification of high-risk UC patients, available treatment options for moderate-to-severe disease, the translation of evidence to best practice when deciding among induction and maintenance therapies, and longitudinal patient assessment and objective monitoring strategies to help achieve treat-to-target (T2T) goals.

Statement of Educational Need

The introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of ulcerative colitis (UC). However, agents of the tumor necrosis factor (TNF) inhibitor class are limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy.1 As the treatment of UC is complex and variable, there is a greater need to better understand the mechanistic profiles, clinical evidence, and placement of advanced, non-TNF inhibitor therapies within the management of moderate-to-severe disease.1 This IBD eHealth Source™, comprised of 4 chapters, will provide published clinical evidence and guideline recommendations surrounding the stratification of high-risk UC patients, available treatment options for moderate-to-severe disease, the translation of evidence to best practice when deciding among induction and maintenance therapies, and longitudinal patient assessment and objective monitoring strategies to help achieve treat-to-target (T2T) goals. Clinical data will be augmented with pertinent qualitative-research–derived insights from expert faculty to provide actionable recommendations for practicing clinicians.

Reference

  1. Coskun M, Vermeire S, Nielsen OH. Trends Pharmacol Sci. 2017;38(2):127-142.

Faculty

Maria T. Abreu, MD
Director, Crohn’s & Colitis Center
Professor of Medicine
Professor of Microbiology and Immunology
Vice Chair for Research, Department of Medicine
Chair, International Organization for the Study of Inflammatory Bowel Disease
University of Miami Miller School of Medicine
Miami, Florida


Jean-Frédéric Colombel, MD
Professor of Medicine, Gastroenterology
Director, Inflammatory Bowel Disease Center
Icahn School of Medicine at Mount Sinai
New York, New York

Disclosure of Conflicts of Interest

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Maria T. Abreu, MD
Consultant/Independent Contractor: AbbVie Inc., Alimentiv, Arena Pharmaceuticals, Inc., Bellatrix Pharmaceuticals, Inc., Bristol Myers Squibb, Cosmo Bio USA, Eli Lilly and Company, Gilead Sciences, Inc., Imedex, LLC, Janssen Pharmaceuticals, Inc., Prometheus Biosciences, Takeda Pharmaceuticals U.S.A., Inc.; Grant/Research Support: Pfizer Inc., Prometheus Biosciences, Takeda Pharmaceuticals U.S.A., Inc.; Honoraria (general): AbbVie Inc., Bellatrix Pharmaceuticals, Inc., Bristol Myers Squibb, Eli Lilly and Company, Gilead Sciences, Inc., Janssen Ortho, LLC, Prometheus Biosciences; Honoraria (teaching, lecturing, or speaking): Alimentiv Inc., Arena Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Microba Life Sciences, PRIME Education, LLC, Takeda Pharmaceuticals U.S.A., Inc., UCB S.A.

Jean-Frédéric Colombel, MD
Consultant/Independent Contractor: AbbVie Inc., Amgen Inc., Arena Pharmaceuticals, Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals, Galmed Research, Genentech, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Inc., Merck & Co., Inc., Microba Life Sciences, Novartis International AG, PBM Capital Group, Pfizer Inc., Sanofi S.A., Takeda Pharmaceuticals U.S.A., Inc., TiGenix, Vifor Pharma Group; Grant/Research Support: AbbVie Inc., Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc.; Stock Shareholder: Intestinal Biotech Development; Other/Royalty (lectures): AbbVie Inc., Amgen Inc., Allergan, Inc., Ferring Pharmaceuticals, Shire plc, Takeda Pharmaceuticals U.S.A., Inc.

The following planners and managers have no relevant financial relationships with ineligible companies:

Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Kim Rodriguez, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME
1.5 AMA PRA Category 1 Credit(s)
Released: October 15, 2021
Expires: October 15, 2022
90 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of clinical gastroenterologists and specialist nurse practitioners and physician assistants involved in the treatment of patients with ulcerative colitis (UC).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Appropriately assess disease severity and activity to identify high-risk patients with UC who may be candidates for advanced treatment with biologics or small molecule inhibitor agents
  • Describe guideline recommendations and clinical trial evidence surrounding induction and maintenance therapies for moderate-to-severe UC
  • Implement treat-to-target strategies that utilize objective measures of remission as well as patient reported outcomes (PROs) to reach patient-centered treatment goals
  • Translate evidence to informed therapeutic selection when evaluating the positioning of biologics and small molecule inhibitors for first-line induction, maintenance, or next-line therapy

Activity Description

This multimedia IBD eHealth Source™ will provide published clinical evidence and guideline recommendations surrounding the stratification of high-risk UC patients, available treatment options for moderate-to-severe disease, the translation of evidence to best practice when deciding among induction and maintenance therapies, and longitudinal patient assessment and objective monitoring strategies to help achieve treat-to-target (T2T) goals.

Statement of Educational Need

The introduction of biologic therapies that target underlying disease processes has dramatically changed the treatment of ulcerative colitis (UC). However, agents of the tumor necrosis factor (TNF) inhibitor class are limited by primary nonresponse and loss of response in a substantial proportion of patients, disease relapse after cessation of therapy, immunogenicity, and adverse effects such as risk for infection and malignancy.1 As the treatment of UC is complex and variable, there is a greater need to better understand the mechanistic profiles, clinical evidence, and placement of advanced, non-TNF inhibitor therapies within the management of moderate-to-severe disease.1 This IBD eHealth Source™, comprised of 4 chapters, will provide published clinical evidence and guideline recommendations surrounding the stratification of high-risk UC patients, available treatment options for moderate-to-severe disease, the translation of evidence to best practice when deciding among induction and maintenance therapies, and longitudinal patient assessment and objective monitoring strategies to help achieve treat-to-target (T2T) goals. Clinical data will be augmented with pertinent qualitative-research–derived insights from expert faculty to provide actionable recommendations for practicing clinicians.

Reference

  1. Coskun M, Vermeire S, Nielsen OH. Trends Pharmacol Sci. 2017;38(2):127-142.

Faculty

Maria T. Abreu, MD
Director, Crohn’s & Colitis Center
Professor of Medicine
Professor of Microbiology and Immunology
Vice Chair for Research, Department of Medicine
Chair, International Organization for the Study of Inflammatory Bowel Disease
University of Miami Miller School of Medicine
Miami, Florida


Jean-Frédéric Colombel, MD
Professor of Medicine, Gastroenterology
Director, Inflammatory Bowel Disease Center
Icahn School of Medicine at Mount Sinai
New York, New York

Disclosure of Conflicts of Interest

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Maria T. Abreu, MD
Consultant/Independent Contractor: AbbVie Inc., Alimentiv, Arena Pharmaceuticals, Inc., Bellatrix Pharmaceuticals, Inc., Bristol Myers Squibb, Cosmo Bio USA, Eli Lilly and Company, Gilead Sciences, Inc., Imedex, LLC, Janssen Pharmaceuticals, Inc., Prometheus Biosciences, Takeda Pharmaceuticals U.S.A., Inc.; Grant/Research Support: Pfizer Inc., Prometheus Biosciences, Takeda Pharmaceuticals U.S.A., Inc.; Honoraria (general): AbbVie Inc., Bellatrix Pharmaceuticals, Inc., Bristol Myers Squibb, Eli Lilly and Company, Gilead Sciences, Inc., Janssen Ortho, LLC, Prometheus Biosciences; Honoraria (teaching, lecturing, or speaking): Alimentiv Inc., Arena Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Microba Life Sciences, PRIME Education, LLC, Takeda Pharmaceuticals U.S.A., Inc., UCB S.A.

Jean-Frédéric Colombel, MD
Consultant/Independent Contractor: AbbVie Inc., Amgen Inc., Arena Pharmaceuticals, Inc., Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals, Galmed Research, Genentech, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Kaleido Biosciences, Imedex, Immunic, Iterative Scopes, Inc., Merck & Co., Inc., Microba Life Sciences, Novartis International AG, PBM Capital Group, Pfizer Inc., Sanofi S.A., Takeda Pharmaceuticals U.S.A., Inc., TiGenix, Vifor Pharma Group; Grant/Research Support: AbbVie Inc., Janssen Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc.; Stock Shareholder: Intestinal Biotech Development; Other/Royalty (lectures): AbbVie Inc., Amgen Inc., Allergan, Inc., Ferring Pharmaceuticals, Shire plc, Takeda Pharmaceuticals U.S.A., Inc.

The following planners and managers have no relevant financial relationships with ineligible companies:

Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Kim Rodriguez, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Ikuo Hirano, MD
1 CME
Integrity Continuing Education, Inc.
Putting the Pieces in Place: The Impact of Recent Pathophysiology Insights and Emerging Therapeutic Strategies to Address Unmet Treatment Needs in Eosinophilic Esophagitis (EoE)

Putting the Pieces in Place: The Impact of Recent Pathophysiology Insights and Emerging Therapeutic Strategies to Address Unmet Treatment Needs in Eosinophilic Esophagitis (EoE)

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: September 29, 2021
Expires: September 29, 2022
60 minutes to complete

Accredited By

Target Audience

Gastroenterologists, allergists, immunologists, pediatric gastroenterologists, pediatric allergists/immunologists, specialty nurse practitioners, and physician assistants

Learning Objectives

  • Summarize criteria and diagnostic tests to accurately diagnose EoE in a timely manner
  • Interpret the recently updated guidelines for the treatment and management of EoE
  • Articulate the latest insights into pathophysiology on therapeutic strategies to address the unmet needs in EoE
  • Evaluate the utility of biologic agents in overcoming limitations of available treatment and in addressing the pathophysiology of EoE
  • Employ patient-centered approaches to improve outcomes in EoE

Activity Description

This interactive educational program will summarize the criteria and methodologies required to accurately diagnose EoE, while outlining updated guidelines to ensure optimal treatment. Recent clinical evidence will be reviewed supporting the role of emerging biologic agents in addressing current EoE care gaps and patient case scenarios will illustrate the utility of these agents in clinical practice.

Statement of Educational Need

Eosinophilic esophagitis (EoE) is not only diagnostically challenging, but patients with EoE face high healthcare costs, suboptimal outcomes, poor quality of life, and a lack of efficacious therapies. While the standard of care comes with important limitations, recent insights into the pathophysiology of this esophageal disease have led to new and emerging biologic therapies with the potential to improve patient outcomes. The unmet treatment needs and unique challenges of EoE for both clinicians and patients, combined with recent advances in therapeutic options, highlight the critical need for clinicians to understand how to integrate these new agents in clinical treatment paradigms.

Program Chair

Ikuo Hirano, MD
Director, Esophageal Center at
Northwestern University, Feinberg School of Medicine
Professor of Medicine
Northwestern University, Feinberg School of Medicine
Chicago, Illinois

Faculty

Edmond S. Chan, MD, FRCPC, FCSACI, FAAAAI
Head, Division of Allergy & Immunology
Department of Pediatrics
Clinical Professor, The University of British Columbia
Clinical Investigator, BC Children’s Hospital Research Institute
BC Children’s Hospital
Vancouver, British Columbia


Mirna Chehade, MD, MPH, AGAF, FAAAAI
Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Ikuo Hirano, MD (Program Chair)
Consulting Fees – Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Calypso, Celgene/Receptos/Bristol Myers Squibb, Eli Lilly, EsoCap Biotech, Gossamer Bio, Parexel, Regeneron, Sanofi, Shire/Takeda
Contracted Research – Adare/Ellodi, Allakos, AstraZeneca, Meritage, Receptos/Bristol Myers Squibb, Regeneron, Shire/Takeda

Edmond S. Chan, MD, FRCPC, FCSACI, FAAAAI
Contracted Research – DBV Technologies
Consulting Fees – Pfizer, Pediapharm, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, Avir Pharma

Mirna Chehade, MD, MPH, AGAF, FAAAAI
Consulting Fees – Regeneron, Allakos, Adare/Ellodi, Shire/Takeda, AstraZeneca, Sanofi, Bristol Myers Squibb
Contracted Research – Regeneron, Allakos, Shire/Takeda, AstraZeneca, Adare/Ellodi, Danone

The following project managers/planners: Donna Fausak and Maria Rovere, MTSC, reported that they or their spouse/life partner, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of September 29, 2021, through September 29, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: September 29, 2021
Expires: September 29, 2022
60 minutes to complete

Accredited By

Target Audience

Gastroenterologists, allergists, immunologists, pediatric gastroenterologists, pediatric allergists/immunologists, specialty nurse practitioners, and physician assistants

Learning Objectives

  • Summarize criteria and diagnostic tests to accurately diagnose EoE in a timely manner
  • Interpret the recently updated guidelines for the treatment and management of EoE
  • Articulate the latest insights into pathophysiology on therapeutic strategies to address the unmet needs in EoE
  • Evaluate the utility of biologic agents in overcoming limitations of available treatment and in addressing the pathophysiology of EoE
  • Employ patient-centered approaches to improve outcomes in EoE

Activity Description

This interactive educational program will summarize the criteria and methodologies required to accurately diagnose EoE, while outlining updated guidelines to ensure optimal treatment. Recent clinical evidence will be reviewed supporting the role of emerging biologic agents in addressing current EoE care gaps and patient case scenarios will illustrate the utility of these agents in clinical practice.

Statement of Educational Need

Eosinophilic esophagitis (EoE) is not only diagnostically challenging, but patients with EoE face high healthcare costs, suboptimal outcomes, poor quality of life, and a lack of efficacious therapies. While the standard of care comes with important limitations, recent insights into the pathophysiology of this esophageal disease have led to new and emerging biologic therapies with the potential to improve patient outcomes. The unmet treatment needs and unique challenges of EoE for both clinicians and patients, combined with recent advances in therapeutic options, highlight the critical need for clinicians to understand how to integrate these new agents in clinical treatment paradigms.

Program Chair

Ikuo Hirano, MD
Director, Esophageal Center at
Northwestern University, Feinberg School of Medicine
Professor of Medicine
Northwestern University, Feinberg School of Medicine
Chicago, Illinois

Faculty

Edmond S. Chan, MD, FRCPC, FCSACI, FAAAAI
Head, Division of Allergy & Immunology
Department of Pediatrics
Clinical Professor, The University of British Columbia
Clinical Investigator, BC Children’s Hospital Research Institute
BC Children’s Hospital
Vancouver, British Columbia


Mirna Chehade, MD, MPH, AGAF, FAAAAI
Associate Professor of Pediatrics and Medicine
Director, Mount Sinai Center for Eosinophilic Disorders
Icahn School of Medicine at Mount Sinai
New York, New York

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Ikuo Hirano, MD (Program Chair)
Consulting Fees – Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Calypso, Celgene/Receptos/Bristol Myers Squibb, Eli Lilly, EsoCap Biotech, Gossamer Bio, Parexel, Regeneron, Sanofi, Shire/Takeda
Contracted Research – Adare/Ellodi, Allakos, AstraZeneca, Meritage, Receptos/Bristol Myers Squibb, Regeneron, Shire/Takeda

Edmond S. Chan, MD, FRCPC, FCSACI, FAAAAI
Contracted Research – DBV Technologies
Consulting Fees – Pfizer, Pediapharm, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, Avir Pharma

Mirna Chehade, MD, MPH, AGAF, FAAAAI
Consulting Fees – Regeneron, Allakos, Adare/Ellodi, Shire/Takeda, AstraZeneca, Sanofi, Bristol Myers Squibb
Contracted Research – Regeneron, Allakos, Shire/Takeda, AstraZeneca, Adare/Ellodi, Danone

The following project managers/planners: Donna Fausak and Maria Rovere, MTSC, reported that they or their spouse/life partner, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of September 29, 2021, through September 29, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

Bruce E. Sands, MD, MS
0.50 CME / CNE
Postgraduate Institute for Medicine
Activity 2: This or That? An Analysis of Real-World Studies Investigating Biologics in Crohn’s Disease (CD)

Activity 2: This or That? An Analysis of Real-World Studies Investigating Biologics in Crohn’s Disease (CD)

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: September 10, 2021
Expires: September 10, 2022
30 minutes to complete

Provided By

Jointly provided by Postgraduate Institute for Medicine and Integritas Communications

Statement of Commercial Support

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This activity is intended for clinical gastroenterologists, gastroenterology specialist nurse practitioners (NPs), and physician assistants (PAs) engaged in the care of patients with ulcerative colitis (UC) and Crohn’s disease (CD).

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

  • Evaluate outcomes from real-world comparative studies investigating the efficacy and safety of biologic therapies within the treatment of CD
  • Inform therapeutic decisions regarding the use of non–tumor necrosis factor (TNF) inhibitor therapies for CD with the latest evidence, expert recommendations, and patient/disease profiles

Program Description

During this guided journal club tour, Dr. Sands will review and discuss the real-world effectiveness and safety of vedolizumab and ustekinumab according to outcomes from 2 individual cohort studies with the goal of indirectly comparing results to determine the best use of these therapies within the management of patients with moderate to severe Crohn’s disease. Currently, head-to-head studies are lacking among advanced, non-TNF inhibitor therapies for Crohn’s disease. Furthermore, although real-world data are also scarce, these types of studies can be used to bridge knowledge gaps that may not be addressed by controlled clinical trials.

Faculty

Bruce E. Sands, MD, MS
Dr. Burrill B. Crohn Professor of Medicine
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, New York

Dr. Bruce Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. Dr. Sands was awarded his undergraduate and medical degrees from Boston University in Massachusetts, and trained in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. After completing his gastroenterology fellowship at the Massachusetts General Hospital (MGH) in Boston, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology.

Dr. Sands is widely recognized for his innovative treatment of Crohn’s disease and ulcerative colitis and for his clinical investigations of new therapeutics. Dr. Sands’ research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD patients in Rhode Island, a project funded by both the National Institutes of Health and the Centers for Disease Control and Prevention. Dr. Sands has served as an Associate Editor for the journal Gastroenterology, and has published over 200 original manuscripts in leading journals such as Gut, Gastroenterology, and the American Journal of Gastroenterology. He was the lead investigator of the landmark studies ACCENT 2, UNIFI, and VARSITY, published in the New England Journal of Medicine.

Dr. Sands is a past chair of the Clinical Research Alliance of the Crohn’s and Colitis Foundation of America and served as chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association. Additionally, Dr. Sands was the chair of the International Organization for the Study of IBD (IOIBD). In 2016, Dr. Sands was awarded the Dr. Henry Janowitz Lifetime Achievement Award from the Crohn’s and Colitis Foundation of America, that organization’s highest honor.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Bruce E. Sands, MD, MS
Consulting Fees: Abivax SA, Arena Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion Healthcare Co., Ltd., Galápagos NV, Gossamer Bio, InDex Pharmaceuticals Holding AB, Janssen Pharmaceutica NV, Johnson & Johnson, Kaleido, Eli Lilly and Company, Morphic Therapeutic, Pfizer Inc., Prometheus Biosciences, Inc., Takeda Pharmaceuticals U.S.A., Inc., Target RWE, Ventyx Biosciences, Vivante Health
Honoraria: Takeda Pharmaceuticals U.S.A., Inc.

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Method of Participation and Request for Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity. 

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com or by visiting: www.pimed.com.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit Designation

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.50 contact hour(s).

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: September 10, 2021
Expires: September 10, 2022
30 minutes to complete

Provided By

Jointly provided by Postgraduate Institute for Medicine and Integritas Communications

Statement of Commercial Support

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This activity is intended for clinical gastroenterologists, gastroenterology specialist nurse practitioners (NPs), and physician assistants (PAs) engaged in the care of patients with ulcerative colitis (UC) and Crohn’s disease (CD).

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

  • Evaluate outcomes from real-world comparative studies investigating the efficacy and safety of biologic therapies within the treatment of CD
  • Inform therapeutic decisions regarding the use of non–tumor necrosis factor (TNF) inhibitor therapies for CD with the latest evidence, expert recommendations, and patient/disease profiles

Program Description

During this guided journal club tour, Dr. Sands will review and discuss the real-world effectiveness and safety of vedolizumab and ustekinumab according to outcomes from 2 individual cohort studies with the goal of indirectly comparing results to determine the best use of these therapies within the management of patients with moderate to severe Crohn’s disease. Currently, head-to-head studies are lacking among advanced, non-TNF inhibitor therapies for Crohn’s disease. Furthermore, although real-world data are also scarce, these types of studies can be used to bridge knowledge gaps that may not be addressed by controlled clinical trials.

Faculty

Bruce E. Sands, MD, MS
Dr. Burrill B. Crohn Professor of Medicine
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, New York

Dr. Bruce Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. Dr. Sands was awarded his undergraduate and medical degrees from Boston University in Massachusetts, and trained in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. After completing his gastroenterology fellowship at the Massachusetts General Hospital (MGH) in Boston, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology.

Dr. Sands is widely recognized for his innovative treatment of Crohn’s disease and ulcerative colitis and for his clinical investigations of new therapeutics. Dr. Sands’ research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD patients in Rhode Island, a project funded by both the National Institutes of Health and the Centers for Disease Control and Prevention. Dr. Sands has served as an Associate Editor for the journal Gastroenterology, and has published over 200 original manuscripts in leading journals such as Gut, Gastroenterology, and the American Journal of Gastroenterology. He was the lead investigator of the landmark studies ACCENT 2, UNIFI, and VARSITY, published in the New England Journal of Medicine.

Dr. Sands is a past chair of the Clinical Research Alliance of the Crohn’s and Colitis Foundation of America and served as chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association. Additionally, Dr. Sands was the chair of the International Organization for the Study of IBD (IOIBD). In 2016, Dr. Sands was awarded the Dr. Henry Janowitz Lifetime Achievement Award from the Crohn’s and Colitis Foundation of America, that organization’s highest honor.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Bruce E. Sands, MD, MS
Consulting Fees: Abivax SA, Arena Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion Healthcare Co., Ltd., Galápagos NV, Gossamer Bio, InDex Pharmaceuticals Holding AB, Janssen Pharmaceutica NV, Johnson & Johnson, Kaleido, Eli Lilly and Company, Morphic Therapeutic, Pfizer Inc., Prometheus Biosciences, Inc., Takeda Pharmaceuticals U.S.A., Inc., Target RWE, Ventyx Biosciences, Vivante Health
Honoraria: Takeda Pharmaceuticals U.S.A., Inc.

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Method of Participation and Request for Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity. 

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com or by visiting: www.pimed.com.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit Designation

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.50 contact hour(s).

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Bruce E. Sands, MD, MS
1.00 CME / CNE
Postgraduate Institute for Medicine
Activity 1: Beyond TNF Inhibitors in Ulcerative Colitis (UC): An Expert Tour of Data That Will Help You Navigate the Guidelines

Activity 1: Beyond TNF Inhibitors in Ulcerative Colitis (UC): An Expert Tour of Data That Will Help You Navigate the Guidelines

Start

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: September 10, 2021
Expires: September 10, 2022
60 minutes to complete

Provided By

Jointly provided by Postgraduate Institute for Medicine and Integritas Communications

Statement of Commercial Support

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This activity is intended for clinical gastroenterologists, gastroenterology specialist nurse practitioners (NPs), and physician assistants (PAs) engaged in the care of patients with ulcerative colitis (UC) and Crohn’s disease (CD).

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

  • Comprehensively evaluate and risk stratify patients with UC to identify individuals who should be managed with advanced therapies
  • Analyze clinical evidence of current biologic and small molecule inhibitor therapies for UC, including head-to-head trials and comparative meta-analyses
  • Utilize guideline recommendations and available clinical evidence to inform first-line treatment selection of advanced therapies for the induction of remission in UC

Program Description

During this guided tour of the American Gastroenterological Association (AGA) Clinical Practice Guidelines, Dr. Sands will review and discuss recommendations that center on the outpatient management of moderate to severe ulcerative colitis. Currently, there are an increasing number of effective non–tumor necrosis factor (TNF) inhibitor therapeutic options available for the treatment of UC. However, utilization of these advanced therapies may present a challenge to current clinical practice as guidance on their positioning within the treatment algorithm is limited and often based on indirect evidence. Therefore, Dr. Sands will walk learners through the publication while providing his interpretation and evaluation of recommendations and highlight key findings to consider when determining the best treatment strategy for each patient.

Faculty

Bruce E. Sands, MD, MS
Dr. Burrill B. Crohn Professor of Medicine
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, New York

Dr. Bruce Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. Dr. Sands was awarded his undergraduate and medical degrees from Boston University in Massachusetts, and trained in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. After completing his gastroenterology fellowship at the Massachusetts General Hospital (MGH) in Boston, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology.

Dr. Sands is widely recognized for his innovative treatment of Crohn’s disease and ulcerative colitis and for his clinical investigations of new therapeutics. Dr. Sands’ research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD patients in Rhode Island, a project funded by both the National Institutes of Health and the Centers for Disease Control and Prevention. Dr. Sands has served as an Associate Editor for the journal Gastroenterology, and has published over 200 original manuscripts in leading journals such as Gut, Gastroenterology, and the American Journal of Gastroenterology. He was the lead investigator of the landmark studies ACCENT 2, UNIFI, and VARSITY, published in the New England Journal of Medicine.

Dr. Sands is a past chair of the Clinical Research Alliance of the Crohn’s and Colitis Foundation of America and served as chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association. Additionally, Dr. Sands was the chair of the International Organization for the Study of IBD (IOIBD). In 2016, Dr. Sands was awarded the Dr. Henry Janowitz Lifetime Achievement Award from the Crohn’s and Colitis Foundation of America, that organization’s highest honor.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Bruce E. Sands, MD, MS
Consulting Fees: Abivax SA, Arena Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion Healthcare Co., Ltd., Galápagos NV, Gossamer Bio, InDex Pharmaceuticals Holding AB, Janssen Pharmaceutica NV, Johnson & Johnson, Kaleido, Eli Lilly and Company, Morphic Therapeutic, Pfizer Inc., Prometheus Biosciences, Inc., Takeda Pharmaceuticals U.S.A., Inc., Target RWE, Ventyx Biosciences, Vivante Health
Honoraria: Takeda Pharmaceuticals U.S.A., Inc.

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Method of Participation and Request for Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity. 

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com or by visiting: www.pimed.com.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit Designation

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: September 10, 2021
Expires: September 10, 2022
60 minutes to complete

Provided By

Jointly provided by Postgraduate Institute for Medicine and Integritas Communications

Statement of Commercial Support

This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This activity is intended for clinical gastroenterologists, gastroenterology specialist nurse practitioners (NPs), and physician assistants (PAs) engaged in the care of patients with ulcerative colitis (UC) and Crohn’s disease (CD).

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

  • Comprehensively evaluate and risk stratify patients with UC to identify individuals who should be managed with advanced therapies
  • Analyze clinical evidence of current biologic and small molecule inhibitor therapies for UC, including head-to-head trials and comparative meta-analyses
  • Utilize guideline recommendations and available clinical evidence to inform first-line treatment selection of advanced therapies for the induction of remission in UC

Program Description

During this guided tour of the American Gastroenterological Association (AGA) Clinical Practice Guidelines, Dr. Sands will review and discuss recommendations that center on the outpatient management of moderate to severe ulcerative colitis. Currently, there are an increasing number of effective non–tumor necrosis factor (TNF) inhibitor therapeutic options available for the treatment of UC. However, utilization of these advanced therapies may present a challenge to current clinical practice as guidance on their positioning within the treatment algorithm is limited and often based on indirect evidence. Therefore, Dr. Sands will walk learners through the publication while providing his interpretation and evaluation of recommendations and highlight key findings to consider when determining the best treatment strategy for each patient.

Faculty

Bruce E. Sands, MD, MS
Dr. Burrill B. Crohn Professor of Medicine
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, New York

Dr. Bruce Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. Dr. Sands was awarded his undergraduate and medical degrees from Boston University in Massachusetts, and trained in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. After completing his gastroenterology fellowship at the Massachusetts General Hospital (MGH) in Boston, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology.

Dr. Sands is widely recognized for his innovative treatment of Crohn’s disease and ulcerative colitis and for his clinical investigations of new therapeutics. Dr. Sands’ research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD patients in Rhode Island, a project funded by both the National Institutes of Health and the Centers for Disease Control and Prevention. Dr. Sands has served as an Associate Editor for the journal Gastroenterology, and has published over 200 original manuscripts in leading journals such as Gut, Gastroenterology, and the American Journal of Gastroenterology. He was the lead investigator of the landmark studies ACCENT 2, UNIFI, and VARSITY, published in the New England Journal of Medicine.

Dr. Sands is a past chair of the Clinical Research Alliance of the Crohn’s and Colitis Foundation of America and served as chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association. Additionally, Dr. Sands was the chair of the International Organization for the Study of IBD (IOIBD). In 2016, Dr. Sands was awarded the Dr. Henry Janowitz Lifetime Achievement Award from the Crohn’s and Colitis Foundation of America, that organization’s highest honor.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Bruce E. Sands, MD, MS
Consulting Fees: Abivax SA, Arena Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion Healthcare Co., Ltd., Galápagos NV, Gossamer Bio, InDex Pharmaceuticals Holding AB, Janssen Pharmaceutica NV, Johnson & Johnson, Kaleido, Eli Lilly and Company, Morphic Therapeutic, Pfizer Inc., Prometheus Biosciences, Inc., Takeda Pharmaceuticals U.S.A., Inc., Target RWE, Ventyx Biosciences, Vivante Health
Honoraria: Takeda Pharmaceuticals U.S.A., Inc.

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Method of Participation and Request for Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity. 

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com or by visiting: www.pimed.com.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit Designation

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Evan S. Dellon, MD, MPH
0.50 CME / MOC
RMEI Medical Education, LLC
Assessing the Potential Patient Care Implications of New Data in Eosinophilic Esophagitis

Assessing the Potential Patient Care Implications of New Data in Eosinophilic Esophagitis

Start

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Points
Released: July 14, 2021
Expires: July 13, 2022
30 minutes to complete

Provided By

This activity is provided by AGA Institute and has been developed through a collaboration between AGA Institute and RMEI Medical Education, LLC.

Target Audience

Gastroenterologists, pediatric gastroenterologists, allergy/immunologists, pediatric allergy/immunologists, and other healthcare professionals involved in the treatment of patients with eosinophilic esophagitis (EoE).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Assess recently presented data on current approaches for the management of eosinophilic esophagitis (EoE)
  • Summarize new findings related to immune pathophysiologic pathways and therapeutic targets for EoE
  • Analyze late-breaking data related to the efficacy, safety, and tolerability of new and emerging therapies for treatment of EoE

Activity Description

In this activity, 2 experts in the diagnosis and management of eosinophilic esophagitis (EoE) analyze data on the treatment of this disease that was presented at the 2021 Digestive Disease Week virtual meetings. Topics for discussion include updates on current management approaches for EoE, new research highlighting the pathophysiological underpinnings of EoE, and late-breaking data on emerging treatment approaches for individuals with EoE.

Chair

Evan S. Dellon, MD, MPH
Professor, Medicine
Adjunct Professor, Epidemiology
University of North Carolina School of Medicine
Chapel Hill, NC

Faculty

Amanda B. Muir, MD, MTR
Attending Physician
Children’s Hospital of Philadelphia, Research Institute
Philadelphia, PA

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Evan S. Dellon, MD, MPH, has affiliations with Abbott, AbbVie, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Landos, Morphic, Parexel/Calyx, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda (Consulting Fees).

Amanda B. Muir, MD, MTR, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic (Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to disclose.
Naemat Sandhu, MD, has no financial relationships to disclose.

Disclosure
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AGA Institute designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 70% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AGA Institute at education@gastro.org.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Points
Released: July 14, 2021
Expires: July 13, 2022
30 minutes to complete

Provided By

This activity is provided by AGA Institute and has been developed through a collaboration between AGA Institute and RMEI Medical Education, LLC.

Target Audience

Gastroenterologists, pediatric gastroenterologists, allergy/immunologists, pediatric allergy/immunologists, and other healthcare professionals involved in the treatment of patients with eosinophilic esophagitis (EoE).

Learning Objectives

After completing this activity, the clinician should be able to:

  • Assess recently presented data on current approaches for the management of eosinophilic esophagitis (EoE)
  • Summarize new findings related to immune pathophysiologic pathways and therapeutic targets for EoE
  • Analyze late-breaking data related to the efficacy, safety, and tolerability of new and emerging therapies for treatment of EoE

Activity Description

In this activity, 2 experts in the diagnosis and management of eosinophilic esophagitis (EoE) analyze data on the treatment of this disease that was presented at the 2021 Digestive Disease Week virtual meetings. Topics for discussion include updates on current management approaches for EoE, new research highlighting the pathophysiological underpinnings of EoE, and late-breaking data on emerging treatment approaches for individuals with EoE.

Chair

Evan S. Dellon, MD, MPH
Professor, Medicine
Adjunct Professor, Epidemiology
University of North Carolina School of Medicine
Chapel Hill, NC

Faculty

Amanda B. Muir, MD, MTR
Attending Physician
Children’s Hospital of Philadelphia, Research Institute
Philadelphia, PA

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Evan S. Dellon, MD, MPH, has affiliations with Abbott, AbbVie, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GSK, Gossamer Bio, Landos, Morphic, Parexel/Calyx, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda (Consulting Fees).

Amanda B. Muir, MD, MTR, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

RMEI Medical Education, LLC
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

AGA Institute Reviewers
Alana Persaud, MD, has no financial relationships to disclose.
Faruq Pradhan, MD, FRCPC, has no financial relationships to disclose.
Richard Wu, MD, MPH, has affiliations with Medtronic (Education Grant, In Kind Support).
Kenneth W. Hung, MD, MS, has no financial relationships to disclose.
Naemat Sandhu, MD, has no financial relationships to disclose.

Disclosure
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AGA Institute and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AGA Institute designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 70% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact AGA Institute at education@gastro.org.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

In order to claim MOC points, users must:

  • Review and successfully complete the activity
  • Proceed to the evaluation and provide your ABIM ID and date of birth

MOC points will be submitted to ABIM profiles within 6 to 8 weeks of completion.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Parambir Dulai, MD
0.75 CME / MOC
Postgraduate Institute for Medicine
Empowered Crohn’s Disease Care: Targets, Tools, and Talking to Patients

Empowered Crohn’s Disease Care: Targets, Tools, and Talking to Patients

Start

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the needs of gastroenterologists, GI surgeons, and other GI-focused clinicians who manage patients with Crohn’s disease (CD).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Summarize the benefits of a treat-to-target strategy in Crohn’s disease (CD) aimed at deep remission
  • Use clinical decision support tools to risk stratify patients for individualized CD care
  • Employ shared decision making for patient-centered and empowered CD care

Activity Description

During this activity, 3 inflammatory bowel disease (IBD) experts discuss the latest real-world insights on treat-to-target strategies in CD, tools to help risk stratify patients with CD, and a personalized approach to care.

Statement of Educational Need

The treatment of Crohn’s disease (CD) has typically relied on treatment intensification based on patient symptoms, but emerging evidence suggests that a treat-to-target approach may offer important benefits, including reducing underlying inflammation and improving long-term outcomes. Because the disease course in CD can vary widely, there has been significant effort directed toward developing risk stratification tools and evidence-based guideline management. Despite the evidence supporting the usefulness of patient-specific risk stratification, many patients with CD suffer disease progression and complications. When patients are involved in their own care through shared decision making, they are more educated about treatment options, confident in their treatment plan, and have a better quality of life.

Faculty

Parambir Dulai, MD (Chair)
Assistant Professor
UC San Diego School of Medicine
La Jolla, CA


Corey A. Siegel, MD, MS
Professor of Medicine and of The Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-Director, IBD Center
Dartmouth-Hitchcock Medical Center
Lebanon, NH


David T. Rubin, MD, FACG, AGAF, FACP
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Parambir Dulai, MD, has affiliations with Janssen, Pfizer, Takeda (Consultant); Janssen (Contracted Research).

Corey A. Siegel, MD, MS, has affiliations with CDPATH Risk Prediction Tool (Receipt of Intellectual Property Rights/Patent Holder); AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Prometheus Laboratories, Takeda (Consultant); Pfizer (Contracted Research); ColonaryConcepts, MiTest Health (Stocks, stock options or other ownership interest excluding diversified mutual funds); AbbVie, Janssen, Pfizer, Takeda (Speaker for CME Programs).

David T. Rubin, MD, FACG, AGAF, FACP, has affiliations with AbbVie, AbGenomics, Allergan, Inc., Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Ltd., Bristol Myers Squibb, CDx Diagnostics, Celgene Corp/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A. (formerly Glenmark Pharmaceuticals), InDex Pharmaceuticals, Iterative Scopies, Janssen, Lilly, Materia Prima, Narrow River Management, Pfizer, Prometheus Laboratories, Reistone, Takeda, Techlab, Inc (Consultant); Takeda (Grant Support); American College of Gastroenterology (Board of Trustees); Cornerstones Health, Inc. (non-profit) (Co-Founder, CFO); GoDuRn, LLC (Co-Founder).

Planners and Managers
The Postgraduate Institute for Medicine planners and managers have nothing to disclose. The RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

During the period from July 7, 2021 through July 6, 2022, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For more information about the accreditation of this program, please contact Postgraduate Institute for Medicine Continuing Medical Education Department at inquiries@pimed.com or by calling 303-799-1930.

Activity Details

Free CME/MOC
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Target Audience

This activity is designed to meet the needs of gastroenterologists, GI surgeons, and other GI-focused clinicians who manage patients with Crohn’s disease (CD).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Summarize the benefits of a treat-to-target strategy in Crohn’s disease (CD) aimed at deep remission
  • Use clinical decision support tools to risk stratify patients for individualized CD care
  • Employ shared decision making for patient-centered and empowered CD care

Activity Description

During this activity, 3 inflammatory bowel disease (IBD) experts discuss the latest real-world insights on treat-to-target strategies in CD, tools to help risk stratify patients with CD, and a personalized approach to care.

Statement of Educational Need

The treatment of Crohn’s disease (CD) has typically relied on treatment intensification based on patient symptoms, but emerging evidence suggests that a treat-to-target approach may offer important benefits, including reducing underlying inflammation and improving long-term outcomes. Because the disease course in CD can vary widely, there has been significant effort directed toward developing risk stratification tools and evidence-based guideline management. Despite the evidence supporting the usefulness of patient-specific risk stratification, many patients with CD suffer disease progression and complications. When patients are involved in their own care through shared decision making, they are more educated about treatment options, confident in their treatment plan, and have a better quality of life.

Faculty

Parambir Dulai, MD (Chair)
Assistant Professor
UC San Diego School of Medicine
La Jolla, CA


Corey A. Siegel, MD, MS
Professor of Medicine and of The Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-Director, IBD Center
Dartmouth-Hitchcock Medical Center
Lebanon, NH


David T. Rubin, MD, FACG, AGAF, FACP
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Parambir Dulai, MD, has affiliations with Janssen, Pfizer, Takeda (Consultant); Janssen (Contracted Research).

Corey A. Siegel, MD, MS, has affiliations with CDPATH Risk Prediction Tool (Receipt of Intellectual Property Rights/Patent Holder); AbbVie, Bristol Myers Squibb, Janssen, Lilly, Pfizer, Prometheus Laboratories, Takeda (Consultant); Pfizer (Contracted Research); ColonaryConcepts, MiTest Health (Stocks, stock options or other ownership interest excluding diversified mutual funds); AbbVie, Janssen, Pfizer, Takeda (Speaker for CME Programs).

David T. Rubin, MD, FACG, AGAF, FACP, has affiliations with AbbVie, AbGenomics, Allergan, Inc., Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Ltd., Bristol Myers Squibb, CDx Diagnostics, Celgene Corp/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A. (formerly Glenmark Pharmaceuticals), InDex Pharmaceuticals, Iterative Scopies, Janssen, Lilly, Materia Prima, Narrow River Management, Pfizer, Prometheus Laboratories, Reistone, Takeda, Techlab, Inc (Consultant); Takeda (Grant Support); American College of Gastroenterology (Board of Trustees); Cornerstones Health, Inc. (non-profit) (Co-Founder, CFO); GoDuRn, LLC (Co-Founder).

Planners and Managers
The Postgraduate Institute for Medicine planners and managers have nothing to disclose. The RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity.

During the period from July 7, 2021 through July 6, 2022, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For more information about the accreditation of this program, please contact Postgraduate Institute for Medicine Continuing Medical Education Department at inquiries@pimed.com or by calling 303-799-1930.

Evan Dellon, MD, MPH
2.0 CME
The Academy for Continued Healthcare Learning
Hard to Swallow: Bridging Knowledge Gaps in Eosinophilic Esophagitis

Hard to Swallow: Bridging Knowledge Gaps in Eosinophilic Esophagitis

Start

Activity Details

Free CME
2.0 AMA PRA Category 1 Credit(s)
Released: June 4, 2021
Expires: June 4, 2022
120 minutes to complete

Accredited By

Target Audience

This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify patients with EoE using the latest diagnostic recommendations and criteria
  • Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
  • Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
  • Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
  • Indicate the potential roles of investigational treatments in EoE management plans

Activity Description

Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.

Faculty discussion will focus on:

  • Recognizing and diagnosing EoE
  • Treating EoE as a chronic disease
  • Novel developments in treatment

Statement of Educational Need

EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.

Agenda

Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic Treatment of EoE

Faculty

Evan Dellon, MD, MPH
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine, University of North Carolina at Chapel Hill
Chapel Hill, NC


Raquel Durban, MS, RD, CSP, LDN
Carolina Asthma & Allergy Center
Registered Dietitian
Charlotte, NC


Gary W. Falk, MD, MS
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA


Calies Menard-Katcher, MD, MSCS
Associate Professor of Pediatrics
Associate Director of Clinical Research for the GEDP
Division of Gastroenterology Hepatology and Nutrition
Department of Pediatrics
University of Colorado School of Medicine
Gastrointestinal Eosinophilic Diseases Program
Digestive Health Institute
Children's Hospital Colorado
Aurora, CO


Robert Pesek, MD
Medical Director, Asthma
Medical Director, Eosinophilic Gastrointestinal Disorders Clinic
Associate Professor of Pediatrics and Allergy/Immunology
Arkansas Children's Hospital and the University of Arkansas for Medical Sciences
Little Rock, AR


The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner, Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda

Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose

Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics, Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb, Interpace, Lucid, Regeneron, Shire/Takeda

Calies Menard-Katcher, MD, MSCS
Nothing to disclose

Robert Pesek, MD
Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Activity Details

Free CME
2.0 AMA PRA Category 1 Credit(s)
Released: June 4, 2021
Expires: June 4, 2022
120 minutes to complete

Accredited By

Target Audience

This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify patients with EoE using the latest diagnostic recommendations and criteria
  • Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
  • Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
  • Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
  • Indicate the potential roles of investigational treatments in EoE management plans

Activity Description

Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.

Faculty discussion will focus on:

  • Recognizing and diagnosing EoE
  • Treating EoE as a chronic disease
  • Novel developments in treatment

Statement of Educational Need

EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.

Agenda

Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic Treatment of EoE

Faculty

Evan Dellon, MD, MPH
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine, University of North Carolina at Chapel Hill
Chapel Hill, NC


Raquel Durban, MS, RD, CSP, LDN
Carolina Asthma & Allergy Center
Registered Dietitian
Charlotte, NC


Gary W. Falk, MD, MS
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA


Calies Menard-Katcher, MD, MSCS
Associate Professor of Pediatrics
Associate Director of Clinical Research for the GEDP
Division of Gastroenterology Hepatology and Nutrition
Department of Pediatrics
University of Colorado School of Medicine
Gastrointestinal Eosinophilic Diseases Program
Digestive Health Institute
Children's Hospital Colorado
Aurora, CO


Robert Pesek, MD
Medical Director, Asthma
Medical Director, Eosinophilic Gastrointestinal Disorders Clinic
Associate Professor of Pediatrics and Allergy/Immunology
Arkansas Children's Hospital and the University of Arkansas for Medical Sciences
Little Rock, AR


The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner, Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda

Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose

Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics, Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb, Interpace, Lucid, Regeneron, Shire/Takeda

Calies Menard-Katcher, MD, MSCS
Nothing to disclose

Robert Pesek, MD
Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Pages